A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose whose tumors expressed PD-L1 <1%, according to results from phase III CheckMate -915.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
